Dominant stricture: balloon dilation with or without stent

What is known

• A randomized trial across 9 European centers comparing balloon dilation with short-term stenting (max 2 weeks), followed for 24 months, was ended early after interim analysis showed futility and more adverse events with stenting. ¹
• Stented patients had higher rates of post-ERCP pancreatitis and acute cholangitis than those undergoing balloon dilation alone; the trial found no superiority of stents over dilatation. ^1,2
• Non-randomized/retrospective data suggest dilatation alone and dilatation with stenting are similarly efficacious, but stenting carries significantly higher complication risk, so stenting is reserved for strictures refractory to dilatation. ^3,4
• Multiple sources recommend dilatation of dominant strictures with stenting reserved for cases where post-dilation drainage is inadequate or lumen patency cannot be maintained. ^4–6
• Malignancy (cholangiocarcinoma) should be excluded via brush cytology/biopsy before intervention on a dominant stricture. ^4,7

What is unknown / caveats

• The excerpts do not report long-term patency numbers separating the two approaches
• Whether tailored stent use or fully-covered self-expanding metallic stents would improve outcomes is unknown
• Whether stenting reserved for selected scenarios (e.g., inadequate drainage after dilatation) yields better long-term patency remains unresolved by the retrieved evidence.

References

1. Marya NB, Tabibian JH. Role of endoscopy in the management of primary sclerosing cholangitis. World J Gastrointest Endosc. 2019. PMID: 30788027.

2. Zecher BF, Schramm C. [Immunopathogenesis and therapy of primary sclerosing cholangitis]. Z Gastroenterol. 2026. PMID: 41587553.

3. Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013. PMID: 23454027.

4. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013. PMID: 23827861.

5. Vlăduţ C, Ciocîrlan M, Bilous D, Șandru V, Stan-Ilie M, Panic N, Becheanu G, Jinga M, Costache RS, Costache DO, Diculescu M. An Overview on Primary Sclerosing Cholangitis. J Clin Med. 2020. PMID: 32168787.

6. Huang CS, Lichtenstein DR. Treatment of Biliary Problems in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005. PMID: 15769433.

7. Goldstein Eric S., Rubin Peter H. Endoscopic Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2003;6(3):237-243. PMID: 12744823.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.